# US 2026/0083722 A1 · Bifunctional degraders comprising electrophilic protacs that engage dcaf1 and pharmaceutical compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083722 A1
- Document ID: US20260083722A1
- Status: Published application
- Kind: A1
- Application number: 18/866,614
- Filed: 2023-05-19
- Published: 2026-03-26
- Earliest claimed: 2022-05-19
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Benjamin F. CRAVATT; Yongfeng TAO; Xiaoyu ZHANG; Dave REMILLARD; Ekaterina VINOGRADOVA; Minoru YOKOYAMA; Bruno MELILLO; Stuart SCHREIBER
- Web page: https://patentgrep.com/patent/US20260083722A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 495/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are bifunctional degraders comprising electrophilic PRO-TACs that engage DCAF1 and pharmaceutical compositions comprising the same. The bifunctional degraders are of Formula A-B-C wherein, A is a ligand to a protein of interest, B is a linker that is a bond or a chemical linker that is chemically linked to A and C, and C is a ligand to the E3 ligase substrate receptor DCAF1, wherein the protein of interest is any protein having a ligand that can form a covalent bond with the linker B; and C comprises an azetidinyl acrylamide that forms a covalent bond with C1113 of DCAF1 through a Michael addition reaction.

## Claims

### Claim 1

A bifunctional degrader of Formula (I)
wherein:
A is a ligand to a protein of interest;
B is a linker that is either a bond or a molecular linker that is covalently linked to both A and C; and
C is a ligand to the E3 ligase substrate receptor DCAF1.

### Claim 2 (depends on 1)

The bifunctional degrader of claim 1, wherein:
the protein of interest is a protein having the ability to bind to the ligand A;
B is a molecular linker covalently linking both A and C; and
the ligand C can form a covalent bond with a cysteine residue of DCAF1.

### Claim 3 (depends on 2)

The bifunctional degrader of claim 2, wherein the ligand C is an azetidinyl acrylamide.

### Claim 4 (depends on 3)

The bifunctional degrader of claim 3, wherein the cysteine residue is C1113 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 1 (Accession No. Q9Y4B6-1).

### Claim 5 (depends on 3)

The bifunctional degrader of claim 3, wherein the cysteine residue is C1112 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 2 (Accession No. Q9Y4B6-2).

### Claim 6 (depends on 3)

The bifunctional degrader of claim 3, wherein the cysteine residue is C664 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 3 (Accession No. Q9Y4B6-3).

### Claim 7 (depends on 3)

The bifunctional degrader of claim 3 wherein the azetidine acrylamide forms a covalent link to the cysteine residue of DCAF1 via a Michael addition reaction.

### Claim 8 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is selected from the group consisting of FKBP12, BRD4, an androgen receptor, an estrogen receptor, IRAK4, a JAK protein, BCL-XL, BCL-2, and Stat3.

### Claim 9 (depends on 3)

The bifunctional degrader of claim 3, wherein the azetidinyl acrylamide has the structure of Formula C-1:
wherein:
Ar is a C6-C10 aryl, optionally substituted with 1-3 moieties selected from the group consisting of: halo, hydroxy, cyano, optionally substituted C1-C6 alkyl, —O—(C1-C6 alkyl), optionally substituted C6-C10 aryl, optionally substituted C3-C8 cycloalkyl, —C(═O)—(C1-C6 alkyl), optionally substituted-(C1-C3)n-heterocyclylphenyl, C6-C10 aryl, —(C1-C3)n-linked optionally substituted five- to six-membered heterocyclyl, —(C1-C3)n-linked optionally substituted five- to six-membered heterocyclyl fused to an optionally substituted C6-C10 aryl, and —(C1-C3)n-linked optionally substituted five- to six-membered heteroaryl;
each R1 independently is an optional substituent selected from the group consisting of: halo, cyano, optionally substituted C1-C6 alkyl, —O—C1-C6 alkyl, optionally substituted C6-C10 aryl, optionally substituted C3-C8 cycloalkyl, —C(═O)(C1-C6 alkyl), optionally substituted five- to six-membered heterocyclyl, and optionally substituted five- to six-membered heteroaryl;
n is 0, 1, or 2;
p is 0, 1 or 2;
ring A is a five- or six-membered heteroaryl;
each R2 independently is an optional substituent selected from the group consisting of: halo, cyano, optionally substituted C1-C6 alkyl, —O—C1-C6 alkyl, optionally substituted C6-C10 aryl, optionally substituted C3-C8 cycloalkyl, —C(═O)(C1-C6 alkyl), optionally substituted five- to six-membered heterocyclyl, and optionally substituted five- to six-membered heteroaryl;
q is 0, 1, or 2; and
indicates the point of attachment to the linker B.

### Claim 10 (depends on 9)

The bifunctional degrader of claim 9, wherein:
Ar is substituted with 1-2 substituents selected from the group consisting of halo, hydroxy, cyano, —O—C1-C6alkyl, -alkynylphenyl, flurophenoxy, methoxyphenyl, —((C1-C3)n)-4-(4-methoxyphenyl) piperidine and —(C1-C3)n-linked optionally substituted five- to six-membered heterocyclyl fused to an optionally substituted C6-C10 aryl.

### Claim 11 (depends on 10)

The bifunctional degrader of claim 10, wherein:
the —(C1-C3)n-linked optionally substituted five- to six-membered heterocyclyl fused to an optionally substituted C6-C10 aryl is selected from the group consisting of —((C1-C3)n)-benzo[d][1,3]dioxolyl, —((C1-C3)n)-1,2,3,4-tetrahydroquinoline-1-yl, —((C1-C3)n)-1,2,3,4-tetrahydroisoquinoline-2-yl, —((C1-C3)n)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-2-yl, and —((C1-C3)n)-indoline-1-yl; and
n is 0 or 1.

### Claim 12 (depends on 9)

The bifunctional degrader of claim 9, wherein Formula (C-1) has the formula (C-1a):

### Claim 13 (depends on 9)

The bifunctional degrader of claim 9, wherein
is:

### Claim 14 (depends on 1)

The bifunctional degrader of claim 1, wherein linker B comprises a moiety having ethylene repeat units, the moiety having the formula (B-1)
wherein r is an integer from 1 to 10; or a moiety having ethylene glycol repeat units, the moiety having the formula (B-2)
wherein s is an integer from 1 to 10.

### Claim 15 (depends on 1)

The bifunctional degrader of claim 1, wherein linker B is

### Claim 16 (depends on 1)

The bifunctional degrader of claim 1, wherein linker B is selected from the group consisting of:

### Claim 17 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is FKBP12.

### Claim 18 (depends on 17)

The bifunctional degrader of claim 17, wherein ligand A is SLF, having the structure (A-1):

### Claim 19 (depends on 17)

The bifunctional degrader of claim 17, wherein the linker B is

### Claim 20 (depends on 17)

The bifunctional degrader of claim 17, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is the androgen receptor.

### Claim 22 (depends on 21)

The bifunctional degrader of claim 21, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein in each instance, or * can be a point of attachment for the linker B.

### Claim 23 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is the estrogen receptor.

### Claim 24 (depends on 23)

The bifunctional degrader of claim 23, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein can be a point of attachment for the linker B.

### Claim 25 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is IRAK4.

### Claim 26 (depends on 25)

The bifunctional degrader of claim 25, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein can be a point of attachment for the linker B.

### Claim 27 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is a JAK protein.

### Claim 28 (depends on 27)

The bifunctional degrader of claim 27, wherein the JAK protein is JAK1, JAK2, or JAK3.

### Claim 29 (depends on 27)

The bifunctional degrader of claim 27, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein can be a point of attachment for the linker B.

### Claim 30 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is BCL-XL or BCL-2.

### Claim 31 (depends on 30)

The bifunctional degrader of claim 30, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein can be a point of attachment for the linker B.

### Claim 32 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is Stat3.

### Claim 33 (depends on 32)

The bifunctional degrader of claim 32, wherein ligand A comprises at least one chemical moiety of Formula (A-2):
wherein:
R is:
and
R1 is:
wherein * is the point of attachment for R and R1, and can be a point of attachment for the linker B.

### Claim 34 (depends on 1)

The bifunctional degrader of claim 1, wherein the protein of interest is BRD4.

### Claim 35 (depends on 34)

The bifunctional degrader of claim 34, wherein ligand A comprises at least one chemical moiety selected from the group consisting of:
wherein can be a point of attachment for the linker B.

### Claim 36 (depends on 34)

The bifunctional degrader of claim 34, wherein ligand A is
and the linker B is

### Claim 37 (depends on 36)

The bifunctional degrader of claim 36, having the structure:

### Claim 38 (depends on 1)

A pharmaceutical composition comprising the bifunctional degrader of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, further comprising an additional therapeutic agent.

### Claim 40 (depends on 1)

A method of degrading a protein selected from the group consisting of FKBP12, BRD4, androgen receptor, estrogen receptor, IRAK4, a JAK protein, BCL-XL, BCL-2, and Stat3 in a patient or biological sample, comprising administering to said patient, or contacting said biological sample, with the bifunctional degrader of claim 1.

### Claim 41 (depends on 1)

A method of treating a disorder, disease or condition mediated by a protein selected from the group consisting of FKBP12, BRD4, androgen receptor, estrogen receptor, IRAK4, a JAK protein, BCL-XL, BCL-2, and Stat3, in a patient, comprising administering to the patient a therapeutically effective amount of the degrader of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the disorder, disease or condition is a cancer, a neurodegenerative disease, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a hematopoietic disorder, a metabolic disorder, a condition associated with organ transplantation, an immunodeficiency disorder, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, a pathologic immune condition involving T cell activation, a cardiovascular disorder, and a CNS disorder.

### Claim 43 (depends on 41)

The method of claim 41, further comprising administering an additional therapeutic agent.

### Claim 44

A DCAF1 protein-probe adduct, wherein the probe binds to cysteine residue C1113 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 1 (Accession No. Q9Y4B6-1), cysteine residue C1112 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 2 (Accession No. Q9Y4B6-2), or cysteine residue C664 of DCAF1, wherein the amino acid numbering is based on DCAF1 Isoform 3 (Accession No. Q9Y4B6-3) and wherein the probe comprises an azetidinyl acrylamide moiety.

### Claim 45 (depends on 44)

The DCAF1 protein-probe adduct of claim 44, wherein the probe is a compound of Formula (I):
wherein:
X is selected from the group consisting of halo,

### Claim 46 (depends on 45)

The DCAF1 protein-probe adduct of claim 45, having the structure of Formula (II):
wherein:
S represents the sulfur atom of a cysteine residue C1113, cysteine residue C1112, or cysteine residue C664; and
DP represents the DCAF1 polypeptide.

### Claim 47 (depends on 44)

The DCAF1 protein-probe adduct of claim 44, wherein the probe is selected from the group consisting of:

### Claim 48

A compound of Formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
X is selected from the group consisting of halo,

### Claim 49 (depends on 48)

The compound of claim 48, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 48)

A method of agonizing or antagonizing DCAF1 protein, wherein the amino acid numbering is based on DCAF1 Isoform 1 (Accession No. Q9Y4B6-1), in a patient in need of such agonization or antagonization, or in a biological sample, comprising administering to the patient, or contacting the biological sample with the compound of claim 48, or a pharmaceutically acceptable salt thereof.
